← All trials
NCT00369096
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2006
- Primary completion
- Nov 1, 2008
- Completion date
- May 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 76
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Fundación Renal Iñigo Alvarez De ToledoLead sponsor
- University of BarcelonaOverall official - principal investigator
- Infociencia S.LCollaborator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- Hospital Universitario Arnau de Vilanova de LleidaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.